Literature DB >> 31923133

Comparative Clinical Effectiveness and Safety of Bone Morphogenetic Protein Versus Autologous Iliac Crest Bone Graft in Lumbar Fusion: A Meta-analysis and Systematic Review.

Shichao Liu1, Yinqing Wang, Zeyan Liang, Maochao Zhou, Chunmei Chen.   

Abstract

STUDY
DESIGN: This is a systematic literature review and meta-analysis.
OBJECTIVE: We aimed to evaluate the efficacy and safety of recombinant human bone morphogenetic protein (RhBMP) and autologous iliac crest bone graft (ICBG) in lumbar fusion. SUMMARY OF BACKGROUND DATA: RhBMP has been emphasized in lumbar fusion due to high fusion success rate. However, ICBG remains the criterion standard graft approach for lumbar fusion. The safety and effectiveness of rhBMP are controversial.
METHODS: Prospective randomized controlled trials were searched from PubMed, EMBASE, and Cochrane Central Register of Controlled Trails by using Medical Subject Headings terms "bone morphogenetic protein,' "bone transplantation,' and "spinal fusion.' Two independent investigators screened eligible studies, assessed the bias of original articles, extracted data including fusion success, Oswestry disability index improvement, improved short form 36 questionnaire scores, adverse events and re-operation, and a subgroup analysis. The GRADE approach was used to grade quality of evidence.
RESULTS: Twenty randomized controlled trials (2185 patients) met the inclusion criteria. There were higher fusion success rate (odds ratio [OR] 3.79, 95% confidence interval [CI] 1.88-7.63, P = 0.0002), better improvement of Oswestry Disability Index (mean difference 1.54, 95% CI 0.18-2.89, P = 0.03), and lower re-operation rate (OR 0.59, 95% CI 0.43-0.80, P = 0.0007) in rhBMP group. Heterogeneity was obvious in fusion success rate (I = 58%); hence, a subgroup analysis, based on protein type (rhBMP-2 or rhBMP-7), was performed, which suggested that only rhBMP-2 was better than ICBG for lumbar fusion. There was no difference in the incidence of adverse events between rhBMP and ICBG (OR 0.91, 95% CI 0.70-1.18, P = 0.47).
CONCLUSION: In lumbar fusion, rhBMP-2 exhibited a higher fusion success rate and reduced the risk of re-operation. No difference in complication rate is between rhBMP (rhBMP-2 and rhBMP-7) and ICBG. We suggest rhBMP especially rhBMP-2 as an effective substitute for ICBG for lumbar fusion. LEVEL OF EVIDENCE: 1.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31923133      PMCID: PMC7282484          DOI: 10.1097/BRS.0000000000003372

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.241


  54 in total

1.  Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.

Authors:  Scott D Boden; James Kang; Harvinder Sandhu; John G Heller
Journal:  Spine (Phila Pa 1976)       Date:  2002-12-01       Impact factor: 3.468

2.  Spinal-fusion surgery - the case for restraint.

Authors:  Richard A Deyo; Alf Nachemson; Sohail K Mirza
Journal:  N Engl J Med       Date:  2004-02-12       Impact factor: 91.245

Review 3.  The principles of bony spinal fusion.

Authors:  H H Kaufman; E Jones
Journal:  Neurosurgery       Date:  1989-02       Impact factor: 4.654

Review 4.  Surgical Interbody Research Group--radiographic assessment of interbody fusion devices: fusion criteria for anterior lumbar interbody surgery.

Authors:  J K Burkus; K Foley; R W Haid; J C LeHuec
Journal:  Neurosurg Focus       Date:  2001-04-15       Impact factor: 4.047

5.  Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures.

Authors:  Kevin S Cahill; John H Chi; Arthur Day; Elizabeth B Claus
Journal:  JAMA       Date:  2009-07-01       Impact factor: 56.272

6.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.

Authors:  John T Farrar; James P Young; Linda LaMoreaux; John L Werth; Michael R Poole
Journal:  Pain       Date:  2001-11       Impact factor: 6.961

7.  Off-label use of bone morphogenetic proteins in the United States using administrative data.

Authors:  Kevin L Ong; Marta L Villarraga; Edmund Lau; Leah Y Carreon; Steven M Kurtz; Steven D Glassman
Journal:  Spine (Phila Pa 1976)       Date:  2010-09-01       Impact factor: 3.468

8.  The effect of recombinant human bone morphogenetic protein-2 in single-level posterior lumbar interbody arthrodesis.

Authors:  J Michielsen; J Sys; A Rigaux; C Bertrand
Journal:  J Bone Joint Surg Am       Date:  2013-05-15       Impact factor: 5.284

9.  rhBMP in lumber fusion for lumbar spondylolisthesis: A systematic review and meta-analysis.

Authors:  Peng-Fei Han; Tao-Yu Chen; Zhi-Liang Zhang; Xiao-Dong Li; Peng-Cui Li; Lei Wei; Zhi Lü; Xiao-Chun Wei
Journal:  Chin J Traumatol       Date:  2019-01-07

10.  A meta analysis of lumbar spinal fusion surgery using bone morphogenetic proteins and autologous iliac crest bone graft.

Authors:  Haifei Zhang; Feng Wang; Lin Ding; Zhiyu Zhang; Deri Sun; Xinmin Feng; Jiuli An; Yue Zhu
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

View more
  4 in total

1.  Primary bone augmentation leads to equally stable marginal tissue conditions comparing the use of xenograft blocks infused with BMP-2 and autogenous bone blocks: A 3D analysis after 3 years.

Authors:  Stefan P Bienz; Michael Payer; Jenni Hjerppe; Jürg Hüsler; Norbert Jakse; Patrick R Schmidlin; Christoph H F Hämmerle; Ronald E Jung; Daniel S Thoma
Journal:  Clin Oral Implants Res       Date:  2021-09-28       Impact factor: 5.021

Review 2.  Influence of the TGF-β Superfamily on Osteoclasts/Osteoblasts Balance in Physiological and Pathological Bone Conditions.

Authors:  Jessica Jann; Suzanne Gascon; Sophie Roux; Nathalie Faucheux
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

3.  Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-blinded, open-label, multicenter trial.

Authors:  Jun-Young Choi; Hyun-Jin Park; Sang-Min Park; Chang-Nam Kang; Kwang-Sup Song
Journal:  J Orthop Surg Res       Date:  2022-08-31       Impact factor: 2.677

Review 4.  Novel Surgical Technique for Adolescent Idiopathic Scoliosis: Minimally Invasive Scoliosis Surgery.

Authors:  Sung Cheol Park; Sei Wook Son; Jae Hyuk Yang; Dong-Gune Chang; Seung Woo Suh; Yunjin Nam; Hong Jin Kim
Journal:  J Clin Med       Date:  2022-10-02       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.